Ovarian low-grade serous carcinoma: a comprehensive update.

I. Díaz-Padilla,A. Malpica,L. Minig,L. Chiva,D. Gershenson,A. González-Martín

DOI: https://doi.org/10.1016/j.ygyno.2012.04.029

IF: 5.304

2012-08-01

Gynecologic Oncology

Abstract:

What problem does this paper attempt to address?

Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study

Zoe Swank,Ella Borberg,Yulu Chen,Yasmeen Senussi,Sujata Chalise,Zachary Manickas-Hill,Xu G Yu,Jonathan Z Li,Galit Alter,Timothy J Henrich,J Daniel Kelly,Rebecca Hoh,Sarah A Goldberg,Steven G Deeks,Jeffrey N Martin,Michael J Peluso,Aarthi Talla,Xiaojun Li,Peter Skene,Thomas F Bumol,Troy R Torgerson,Julie L Czartoski,M Juliana McElrath,Elizabeth W Karlson,David R Walt,RECOVER consortium authors

DOI: https://doi.org/10.1016/j.cmi.2024.09.001

Abstract:Objectives: To determine the proportion of individuals with detectable antigen in plasma or serum after SARS-CoV-2 infection and the association of antigen detection with postacute sequelae of COVID-19 (PASC) symptoms. Methods: Plasma and serum samples were collected from adults participating in four independent studies at different time points, ranging from several days up to 14 months post-SARS-CoV-2 infection. The primary outcome measure was to quantify SARS-CoV-2 antigens, including the S1 subunit of spike, full-length spike, and nucleocapsid, in participant samples. The presence of 34 commonly reported PASC symptoms during the postacute period was determined from participant surveys or chart reviews of electronic health records. Results: Of the 1569 samples analysed from 706 individuals infected with SARS-CoV-2, 21% (95% CI, 18-24%) were positive for either S1, spike, or nucleocapsid. Spike was predominantly detected, and the highest proportion of samples was spike positive (20%; 95% CI, 18-22%) between 4 and 7 months postinfection. In total, 578 participants (82%) reported at least one of the 34 PASC symptoms included in our analysis ≥1 month postinfection. Cardiopulmonary, musculoskeletal, and neurologic symptoms had the highest reported prevalence in over half of all participants, and among those participants, 43% (95% CI, 40-45%) on average were antigen-positive. Among the participants who reported no ongoing symptoms (128, 18%), antigen was detected in 28 participants (21%). The presence of antigen was associated with the presence of one or more PASC symptoms, adjusting for sex, age, time postinfection, and cohort (OR, 1.8; 95% CI, 1.4-2.2). Discussion: The findings of this multicohort study indicate that SARS-CoV-2 antigens can be detected in the blood of a substantial proportion of individuals up to 14 months after infection. While approximately one in five asymptomatic individuals was antigen-positive, roughly half of all individuals reporting ongoing cardiopulmonary, musculoskeletal, and neurologic symptoms were antigen-positive.
Early biological markers of post-acute sequelae of SARS-CoV-2 infection

Scott Lu,Michael J. Peluso,David V. Glidden,Michelle C. Davidson,Kara Lugtu,Jesus Pineda-Ramirez,Michel Tassetto,Miguel Garcia-Knight,Amethyst Zhang,Sarah A. Goldberg,Jessica Y. Chen,Maya Fortes-Cobby,Sara Park,Ana Martinez,Matthew So,Aidan Donovan,Badri Viswanathan,Rebecca Hoh,Kevin Donohue,David R. McIlwain,Brice Gaudiliere,Khamal Anglin,Brandon C. Yee,Ahmed Chenna,John W. Winslow,Christos J. Petropoulos,Steven G. Deeks,Melissa Briggs-Hagen,Raul Andino,Claire M. Midgley,Jeffrey N. Martin,Sharon Saydah,J. Daniel Kelly

DOI: https://doi.org/10.1038/s41467-024-51893-7

IF: 16.6

2024-08-31

Nature Communications

Abstract:To understand the roles of acute-phase viral dynamics and host immune responses in post-acute sequelae of SARS-CoV-2 infection (PASC), we enrolled 136 participants within 5 days of their first positive SARS-CoV-2 real-time PCR test. Participants self-collected up to 21 nasal specimens within the first 28 days post-symptom onset; interviewer-administered questionnaires and blood samples were collected at enrollment, days 9, 14, 21, 28, and month 4 and 8 post-symptom onset. Defining PASC as the presence of any COVID-associated symptom at their 4-month visit, we compared viral markers (quantity and duration of nasal viral RNA load, infectious viral load, and plasma N-antigen level) and host immune markers (IL-6, IL-10, TNF-α, IFN-α, IFN-γ, MCP, IP-10, and Spike IgG) over the acute period. Compared to those who fully recovered, those reporting PASC demonstrated significantly higher maximum levels of SARS-CoV-2 RNA and N-antigen, burden of RNA and infectious viral shedding, and lower Spike-specific IgG levels within 9 days post-illness onset. No significant differences were identified among a panel of host immune markers. Our results suggest early viral dynamics and the associated host immune responses play a role in the pathogenesis of PASC, highlighting the importance of understanding early biological markers in the natural history of PASC.

multidisciplinary sciences
Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days in SARS-CoV-2 Negative Post COVID-19 Vaccination Individuals with Post-Acute Sequalae of COVID-19 (PASC)-Like Symptoms

Bruce K. Patterson,Ram Yogendra,Edgar B. Francisco,Emily Long,Amruta Pise,Eric Osgood,John Bream,Mark Kreimer,Devon Jeffers,Christopher Beaty,Richard Vander Heide,Jose Guevara-Coto,Rodrigo A Mora-Rodríguez

DOI: https://doi.org/10.1101/2024.03.24.24304286

2024-03-24

Abstract:There have been concerning reports about people experiencing new onset persistent complications (greater than 30 days) following approved SARS-CoV-2 vaccines (BNT162b2 (Pfizer), mRNA-1273 (Moderna), Janssen (Johnson and Johnson), and ChAdOx1 nCoV-19 (AstraZeneca)). We sought to determine the immunologic abnormalities in these patients and to investigate whether the potential etiology was similar to Post-Acute Sequalae of COVID (PASC), or long COVID. We studied 50 individuals who received one of the approved COVID-19 vaccines and who experienced new onset PASC-like symptoms along with 45 individuals post-vaccination without symptoms as controls. We performed multiplex cytokine/chemokine profiling with machine learning as well as SARS-CoV-2 S1 protein detection on CD16+ monocyte subsets using flow cytometry and mass spectrometry. We determined that post-vaccination individuals with PASC- like symptoms had similar symptoms to PASC patients. When analyzing their immune profile, Post-vaccination individuals had statistically significant elevations of sCD40L (p<0.001), CCL5 (p=0.017), IL-6 (p=0.043), and IL-8 (p=0.022). Machine learning characterized these individuals as PASC using previously developed algorithms. Of the S1 positive post-vaccination patients, we demonstrated by liquid chromatography/ mass spectrometry that these CD16+ cells from post-vaccination patients from all 4 vaccine manufacturers contained S1, S1 mutant and S2 peptide sequences. Post-COVID vaccination individuals with PASC-like symptoms exhibit markers of platelet activation and pro-inflammatory cytokine production, which may be driven by the persistence of SARS-CoV-2 S1 proteins in intermediate and non-classical monocytes. The data from this study also cannot make any inferences on epidemiology and prevalence for persistent post-COVID vaccine symptoms. Thus, further studies and research need to be done to understand the risk factors, likelihood and prevalence of these symptoms.

Primary Care Research
Viral persistence, reactivation, and mechanisms of long COVID

Benjamin Chen,Boris Julg,Sindhu Mohandas,Steven B Bradfute

DOI: https://doi.org/10.7554/eLife.86015

IF: 7.7

2023-05-05

eLife

Abstract:The COVID-19 global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has infected hundreds of millions of individuals. Following COVID-19 infection, a subset can develop a wide range of chronic symptoms affecting diverse organ systems referred to as post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. A National Institutes of Health-sponsored initiative, RECOVER: Researching COVID to Enhance Recovery, has sought to understand the basis of long COVID in a large cohort. Given the range of symptoms that occur in long COVID, the mechanisms that may underlie these diverse symptoms may also be diverse. In this review, we focus on the emerging literature supporting the role(s) that viral persistence or reactivation of viruses may play in PASC. Persistence of SARS-CoV-2 RNA or antigens is reported in some organs, yet the mechanism by which they do so and how they may be associated with pathogenic immune responses is unclear. Understanding the mechanisms of persistence of RNA, antigen or other reactivated viruses and how they may relate to specific inflammatory responses that drive symptoms of PASC may provide a rationale for treatment.

biology
Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19

Michael J Peluso,J Daniel Kelly,Scott Lu,Sarah A Goldberg,Michelle C Davidson,Sujata Mathur,Matthew S Durstenfeld,Matthew A Spinelli,Rebecca Hoh,Viva Tai,Emily A Fehrman,Leonel Torres,Yanel Hernandez,Meghann C Williams,Mireya I Arreguin,Jennifer A Bautista,Lynn H Ngo,Monika Deswal,Sadie E Munter,Enrique O Martinez,Khamal A Anglin,Mariela D Romero,Jacqueline Tavs,Paulina R Rugart,Jessica Y Chen,Hannah M Sans,Victoria W Murray,Payton K Ellis,Kevin C Donohue,Jonathan A Massachi,Jacob O Weiss,Irum Mehdi,Jesus Pineda-Ramirez,Alex F Tang,Megan Wenger,Melissa Assenzio,Yan Yuan,Melissa Krone,Rachel L Rutishauser,Isabel Rodriguez-Barraquer,Bryan Greenhouse,John A Sauceda,Monica Gandhi,Priscilla Y Hsue,Timothy J Henrich,Steven G Deeks,Jeffrey N Martin

DOI: https://doi.org/10.1101/2021.03.11.21252311

2021-03-12

MedRxiv

Abstract:Background: As the coronavirus disease 2019 (COVID-19) pandemic continues and millions remain vulnerable to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing post-acute sequelae of SARS-CoV-2 infection (PASC). Methods: From April 21 to December 31, 2020, we assembled a cohort of consecutive volunteers who a) had documented history of SARS-CoV-2 RNA-positivity; b) were ≥ 2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were able to travel to our site in San Francisco. Participants learned about the study by being identified on medical center-based registries and being notified or by responding to advertisements. At 4-month intervals, we asked participants about physical symptoms that were new or worse compared to the period prior to COVID-19, mental health symptoms and quality of life. We described 4 time periods: 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral specimens were collected at each visit. Results: We have, to date, enrolled 179 adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the acute phase, the most common symptoms were fatigue, fever, myalgia, cough and anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were the most commonly reported symptoms, but a variety of others were endorsed by at least some participants. Some experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with ambulation and performance of usual activities. The median visual analogue scale value rating of general health was lower at 4 and 8 months (80, interquartile range [IQR]: 70-90; and 80, IQR 75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected at nearly 600 participant-visits. Conclusion: Among a cohort of participants enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with persistent physical symptoms through 8 months following onset of COVID-19 with an impact on self-rated overall health. The presence of participants with and without symptoms and ample biological specimens will facilitate study of PASC pathogenesis. Similar evaluations in a population-representative sample will be needed to estimate the population-level prevalence of PASC.
Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infection

Julio A Huapaya,Salina Gairhe,Shreya Kanth,Xin Tian,Cumhur Y Demirkale,David Regenold,Jian Sun,Nicolas F Lynch,Renjie Luo,Alisa Forsberg,Robin Dewar,Tauseef Rehman,Willy Li,Janell Krack,Janaki Kuruppu,Etsubdink A Aboye,Christopher Barnett,Jeffrey R Strich,Richard Davey,Richard Childs,Daniel Chertow,Joseph A Kovacs,Parizad Torabi-Parizi,Anthony F Suffredini

DOI: https://doi.org/10.3389/fimmu.2024.1448780

2024-09-11

Abstract:Background: Limited data are available describing the effects of SARS-CoV-2 breakthrough infections on the plasma proteome. Methods: PCR-positive SARS-CoV-2 patients, enrolled in a natural history study, underwent analysis of the plasma proteome. A prospective cohort of 66 unvaccinated and 24 vaccinated persons with different degrees of infection severity were evaluated acutely (within 40 days of symptom onset), and at three and ten months. Comparisons based on vaccination status alone and unsupervised hierarchical clustering were performed. A second cohort of vaccinated Omicron patients were evaluated acutely and at ten months. Results: Acutely, unvaccinated patients manifested overexpression of proteins involved in immune and inflammatory responses, while vaccinated patients exhibited adaptive immune responses without significant inflammation. At three and ten months, only unvaccinated patients had diminished but sustained inflammatory (C3b, CCL15, IL17RE) and immune responses (DEFA5,TREM1). Both groups had underexpression of pathways essential for cellular function, signaling, and angiogenesis (AKT1, MAPK14, HSPB1) across phases. Unsupervised clustering, based on protein expression, identified four groups of patients with variable vaccination rates demonstrating that additional clinical factors influence the plasma proteome. The proteome of vaccinated Omicron patients did not differ from vaccinated pre-Omicron patients. Conclusions: Vaccination attenuates the inflammatory response to SARS-CoV-2 infection across phases. However, at ten months after symptom onset, changes in the plasma proteome persist in both vaccinated and unvaccinated individuals, which may be relevant to post-acute sequelae of SARS-CoV-2 and other viral infections associated with post-acute infection syndromes.
Prevalence of persistent SARS-CoV-2 in a large community surveillance study

Mahan Ghafari,Matthew Hall,Tanya Golubchik,Daniel Ayoubkhani,Thomas House,George MacIntyre-Cockett,Helen R. Fryer,Laura Thomson,Anel Nurtay,Steven A. Kemp,Luca Ferretti,David Buck,Angie Green,Amy Trebes,Paolo Piazza,Lorne J. Lonie,Ruth Studley,Emma Rourke,Darren L. Smith,Matthew Bashton,Andrew Nelson,Matthew Crown,Clare McCann,Gregory R. Young,Rui Andre Nunes dos Santos,Zack Richards,Mohammad Adnan Tariq,Roberto Cahuantzi,Jeff Barrett,Christophe Fraser,David Bonsall,Ann Sarah Walker,Katrina Lythgoe

DOI: https://doi.org/10.1038/s41586-024-07029-4

IF: 64.8

2024-02-22

Nature

Abstract:Persistent SARS-CoV-2 infections may act as viral reservoirs that could seed future outbreaks 1,2,3,4,5 , give rise to highly divergent lineages 6,7,8 and contribute to cases with post-acute COVID-19 sequelae (long COVID) 9,10 . However, the population prevalence of persistent infections, their viral load kinetics and evolutionary dynamics over the course of infections remain largely unknown. Here, using viral sequence data collected as part of a national infection survey, we identified 381 individuals with SARS-CoV-2 RNA at high titre persisting for at least 30 days, of which 54 had viral RNA persisting at least 60 days. We refer to these as 'persistent infections' as available evidence suggests that they represent ongoing viral replication, although the persistence of non-replicating RNA cannot be ruled out in all. Individuals with persistent infection had more than 50% higher odds of self-reporting long COVID than individuals with non-persistent infection. We estimate that 0.1–0.5% of infections may become persistent with typically rebounding high viral loads and last for at least 60 days. In some individuals, we identified many viral amino acid substitutions, indicating periods of strong positive selection, whereas others had no consensus change in the sequences for prolonged periods, consistent with weak selection. Substitutions included mutations that are lineage defining for SARS-CoV-2 variants, at target sites for monoclonal antibodies and/or are commonly found in immunocompromised people 11,12,13,14 . This work has profound implications for understanding and characterizing SARS-CoV-2 infection, epidemiology and evolution.

multidisciplinary sciences
A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Michael C Sneller,C Jason Liang,Adriana R Marques,Joyce Y Chung,Sujata M Shanbhag,Joseph R Fontana,Haniya Raza,Onyi Okeke,Robin L Dewar,Bryan P Higgins,Katie Tolstenko,Richard W Kwan,Kathleen R Gittens,Catherine A Seamon,Genevieve McCormack,Jacob S Shaw,Grace M Okpali,Melissa Law,Krittin Trihemasava,Brooke D Kennedy,Victoria Shi,J Shawn Justement,Clarisa M Buckner,Jana Blazkova,Susan Moir,Tae-Wook Chun,H Clifford Lane

DOI: https://doi.org/10.7326/M21-4905

Abstract:Background: A substantial proportion of persons who develop COVID-19 report persistent symptoms after acute illness. Various pathophysiologic mechanisms have been implicated in the pathogenesis of postacute sequelae of SARS-CoV-2 infection (PASC). Objective: To characterize medical sequelae and persistent symptoms after recovery from COVID-19 in a cohort of disease survivors and controls. Design: Cohort study. (ClinicalTrials.gov: NCT04411147). Setting: National Institutes of Health Clinical Center, Bethesda, Maryland. Participants: Self-referred adults with laboratory-documented SARS-CoV-2 infection who were at least 6 weeks from symptom onset were enrolled regardless of presence of PASC. A control group comprised persons with no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, recruited regardless of their current health status. Both groups were enrolled over the same period and from the same geographic area. Measurements: All participants had the same evaluations regardless of presence of symptoms, including physical examination, laboratory tests and questionnaires, cognitive function testing, and cardiopulmonary evaluation. A subset also underwent exploratory immunologic and virologic evaluations. Results: 189 persons with laboratory-documented COVID-19 (12% of whom were hospitalized during acute illness) and 120 antibody-negative control participants were enrolled. At enrollment, symptoms consistent with PASC were reported by 55% of the COVID-19 cohort and 13% of control participants. Increased risk for PASC was noted in women and those with a history of anxiety disorder. Participants with findings meeting the definition of PASC reported lower quality of life on standardized testing. Abnormal findings on physical examination and diagnostic testing were uncommon. Neutralizing antibody levels to spike protein were negative in 27% of the unvaccinated COVID-19 cohort and none of the vaccinated COVID-19 cohort. Exploratory studies found no evidence of persistent viral infection, autoimmunity, or abnormal immune activation in participants with PASC. Limitations: Most participants with COVID-19 had mild to moderate acute illness that did not require hospitalization. The prevalence of reported PASC was likely overestimated in this cohort because persons with PASC may have been more motivated to enroll. The study did not capture PASC that resolved before enrollment. Conclusion: A high burden of persistent symptoms was observed in persons after COVID-19. Extensive diagnostic evaluation revealed no specific cause of reported symptoms in most cases. Antibody levels were highly variable after COVID-19. Primary funding source: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Patient and immunological factors associated with delayed clearance of mucosal SARS-CoV-2 RNA and symptom persistence

Mars Stone,Bryan R Spencer,Donald E Warden,Rebecca V Fink,Paula Saa,Jennifer Leddy,Jackie Mulach-Vannoy,Rebecca Townsend,David Krysztof,Alexandria N Hughes,Clara Di Germanio,Debra A Kessler,Steven Kleinman,Michael P Busch,Philip J Norris

DOI: https://doi.org/10.1093/infdis/jiae132

2024-03-13

The Journal of Infectious Diseases

Abstract:Serial blood and mucosal samples were characterized for 102 participants enrolled a median of 7.0 days post-COVID-19 diagnosis. Mucosal RNA was detectable a median 31.5 (95% CI 20.5 - 63.5) days, with persistence ≥1 month associated with obesity (BMI ≥30, OR 3.9, 95% CI 1.2 - 13.8) but not age, sex, or chronic conditions. Fifteen participants had likely reinfection; lower serum anti-S IgG levels were associated with reinfection risk. Nearly half of participants (47%) reported symptoms lasting ≥2-3 months; persistence ≥3 months was associated with BMI ≥30 (OR = 4.2 95% CI 1.1 - 12.8) and peak anti-S and anti-NC antibody levels.

immunology,infectious diseases,microbiology
Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals

Jacqueline M. Leung,Michelle J. Wu,Pouya Kheradpour,Chen Chen,Katherine A. Drake,Gary Tong,Vanessa K. Ridaura,Howard C. Zisser,William A. Conrad,Natalia Hudson,Jared Allen,Christopher Welberry,Celine Parsy-Kowalska,Isabel Macdonald,Victor F. Tapson,James N. Moy,Christopher R. deFilippi,Ivan O. Rosas,Mujeeb Basit,Jerry A. Krishnan,Sairam Parthasarathy,Bellur S. Prabhakar,Mirella Salvatore,Charles C. Kim

DOI: https://doi.org/10.3389/fimmu.2024.1348041

IF: 7.3

2024-01-23

Frontiers in Immunology

Abstract:Background: Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to post-acute sequelae of SARS-CoV-2 (PASC) that can persist for weeks to years following initial viral infection. Clinical manifestations of PASC are heterogeneous and often involve multiple organs. While many hypotheses have been made on the mechanisms of PASC and its associated symptoms, the acute biological drivers of PASC are still unknown. Methods: We enrolled 494 patients with COVID-19 at their initial presentation to a hospital or clinic and followed them longitudinally to determine their development of PASC. From 341 patients, we conducted multi-omic profiling on peripheral blood samples collected shortly after study enrollment to investigate early immune signatures associated with the development of PASC. Results: During the first week of COVID-19, we observed a large number of differences in the immune profile of individuals who were hospitalized for COVID-19 compared to those individuals with COVID-19 who were not hospitalized. Differences between individuals who did or did not later develop PASC were, in comparison, more limited, but included significant differences in autoantibodies and in epigenetic and transcriptional signatures in double-negative 1 B cells, in particular. Conclusions: We found that early immune indicators of incident PASC were nuanced, with significant molecular signals manifesting predominantly in double-negative B cells, compared with the robust differences associated with hospitalization during acute COVID-19. The emerging acute differences in B cell phenotypes, especially in double-negative 1 B cells, in PASC patients highlight a potentially important role of these cells in the development of PASC.

immunology
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection

Michael J Peluso,Dylan Ryder,Robert R Flavell,Yingbing Wang,Jelena Levi,Brian H LaFranchi,Tyler-Marie Deveau,Amanda M Buck,Sadie E Munter,Kofi A Asare,Maya Aslam,Walter Koch,Gyula Szabo,Rebecca Hoh,Monika Deswal,Antonio E Rodriguez,Melissa Buitrago,Viva Tai,Uttam Shrestha,Scott Lu,Sarah A Goldberg,Thomas Dalhuisen,Joshua J Vasquez,Matthew S Durstenfeld,Priscilla Y Hsue,J Daniel Kelly,Nitasha Kumar,Jeffrey N Martin,Aruna Gambhir,Ma Somsouk,Youngho Seo,Steven G Deeks,Zoltan G Laszik,Henry F VanBrocklin,Timothy J Henrich

DOI: https://doi.org/10.1126/scitranslmed.adk3295

2024-07-03

Abstract:The mechanisms of postacute medical conditions and unexplained symptoms after SARS-CoV-2 infection [Long Covid (LC)] are incompletely understood. There is growing evidence that viral persistence, immune dysregulation, and T cell dysfunction may play major roles. We performed whole-body positron emission tomography imaging in a well-characterized cohort of 24 participants at time points ranging from 27 to 910 days after acute SARS-CoV-2 infection using the radiopharmaceutical agent [18F]F-AraG, a selective tracer that allows for anatomical quantitation of activated T lymphocytes. Tracer uptake in the postacute COVID-19 group, which included those with and without continuing symptoms, was higher compared with prepandemic controls in many regions, including the brain stem, spinal cord, bone marrow, nasopharyngeal and hilar lymphoid tissue, cardiopulmonary tissues, and gut wall. T cell activation in the spinal cord and gut wall was associated with the presence of LC symptoms. In addition, tracer uptake in lung tissue was higher in those with persistent pulmonary symptoms specifically. Increased T cell activation in these tissues was also observed in many individuals without LC. Given the high [18F]F-AraG uptake detected in the gut, we obtained colorectal tissue for in situ hybridization of SARS-CoV-2 RNA and immunohistochemical studies in a subset of five participants with LC symptoms. We identified intracellular SARS-CoV-2 single-stranded spike protein-encoding RNA in rectosigmoid lamina propria tissue in all five participants and double-stranded spike protein-encoding RNA in three participants up to 676 days after initial COVID-19, suggesting that tissue viral persistence could be associated with long-term immunologic perturbations.
Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Danrong Shi,Tianhao Weng,Jie Wu,Chunyan Dai,Rui Luo,Keda Chen,Miaojin Zhu,Xiangyun Lu,Linfang Cheng,Qiuqiang Chen,Fumin Liu,Zhigang Wu,Haibo Wu,Changzhong Jin,Miao Guo,Zhe Chen,Nanping Wu,Hangping Yao,Min Zheng

DOI: https://doi.org/10.3389/fimmu.2021.708184

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:There is a worldwide pandemic of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; yet our understanding remains limited on the characteristic of antibodies, especially for dynamic long-term tracking. Sequential serum samples were collected up to 416 days post onset of symptoms (POS) from 102 patients who were hospitalized with coronavirus disease 2019 (COVID-19). Immunoglobulin (Ig)G, IgM, and IgA levels targeting SARS-CoV-2 spike 1 receptor-binding domain (S1-RBD), spike 2 extracellular domain (S2-ECD), and nucleocapsid protein (N) were quantified as well as neutralizing activity. We were pleasantly surprised to find that the antibody remained detective and effective for more than a year POS. We also found the varied reactions of different antibodies as time passed: N-IgA rose most rapidly in the early stage of infection, while S2-IgG was present at a high level in the long time of observation. This study described the long traceable antibody response of the COVID-19 and offered hints about targets to screen for postinfectious immunity and for vaccination development of SARS-CoV-2.
Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

Amy D. Proal,Michael B. VanElzakker

DOI: https://doi.org/10.3389/fmicb.2021.698169

IF: 5.2

2021-06-23

Frontiers in Microbiology

Abstract:The novel virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic of coronavirus disease 2019 (COVID-19). Across the globe, a subset of patients who sustain an acute SARS-CoV-2 infection are developing a wide range of persistent symptoms that do not resolve over the course of many months. These patients are being given the diagnosis Long COVID or Post-acute sequelae of COVID-19 (PASC). It is likely that individual patients with a PASC diagnosis have different underlying biological factors driving their symptoms, none of which are mutually exclusive. This paper details mechanisms by which RNA viruses beyond just SARS-CoV-2 have be connected to long-term health consequences. It also reviews literature on acute COVID-19 and other virus-initiated chronic syndromes such as post-Ebola syndrome or myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) to discuss different scenarios for PASC symptom development. Potential contributors to PASC symptoms include consequences from acute SARS-CoV-2 injury to one or multiple organs, persistent reservoirs of SARS-CoV-2 in certain tissues, re-activation of neurotrophic pathogens such as herpesviruses under conditions of COVID-19 immune dysregulation, SARS-CoV-2 interactions with host microbiome/virome communities, clotting/coagulation issues, dysfunctional brainstem/vagus nerve signaling, ongoing activity of primed immune cells, and autoimmunity due to molecular mimicry between pathogen and host proteins. The individualized nature of PASC symptoms suggests that different therapeutic approaches may be required to best manage care for specific patients with the diagnosis.

microbiology
The Potential Role of Viral Persistence in the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Lorenzo Lupi,Adriana Vitiello,Cristina Parolin,Arianna Calistri,Alfredo Garzino-Demo

DOI: https://doi.org/10.3390/pathogens13050388

IF: 3.7

2024-05-09

Pathogens

Abstract:The infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated not only with the development of acute disease but also with long-term symptoms or post-acute sequelae of SARS-CoV-2 (PASC). Multiple lines of evidence support that some viral antigens and RNA can persist for up to 15 months in multiple organs in the body, often after apparent clearance from the upper respiratory system, possibly leading to the persistence of symptoms. Activation of the immune system to viral antigens is observed for a prolonged time, providing indirect evidence of the persistence of viral elements after acute infection. In the gastrointestinal tract, the persistence of some antigens could stimulate the immune system, shaping the local microbiota with potential systemic effects. All of these interactions need to be investigated, taking into account predisposing factors, multiplicity of pathogenic mechanisms, and stratifying populations of vulnerable individuals, particularly women, children, and immunocompromised individuals, where SARS-CoV-2 may present additional challenges.

microbiology
Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

Francisco Tejerina,Pilar Catalan,Cristina Rodriguez-Grande,Javier Adan,Carmen Rodriguez-Gonzalez,Patricia Muñoz,Teresa Aldamiz,Cristina Diez,Leire Perez,Chiara Fanciulli,Dario Garcia de Viedma,Luis Alcalá,Roberto Alonso,Beatriz Álvarez,Ana Álvarez-Uría,Alexi Arias,Luis Antonio Arroyo,Juan Berenguer,Elena Bermúdez,Emilio Bouza,Almudena Burillo,Ana Candela,Raquel Carrillo,Emilia Cercenado,Alejandro Cobos,Pilar Escribano,Agustín Estévez,Silvia Fernandez,Alicia Galar,Mª Dolores García,Paloma Gijón,Adolfo González,Helmuth Guillén,Jesús Guinea,Laura Vanessa Haces,Martha Kestler,Juan Carlos López,Carmen Narcisa Losada,Marina Machado,Mercedes Marín,Pablo Martín,Paloma Martín,Pedro Montilla,Zaira Moure,María Olmedo,Belén Padilla,María Palomo,Francisco Parras,María Jesús Pérez-Granda,Laura Pérez,Paula Pescador,Elena Reigadas,Cristina Rincón,Belén Rodríguez,Sara Rodríguez,Adriana Rojas,María Jesús Ruiz-Serrano,Carlos Sánchez,Mar Sánchez,Julia Serrano,Maricela Valerio,Mª Cristina Veintimilla,Lara Vesperinas,Teresa Vicente,Sofía de la Villa,

DOI: https://doi.org/10.1186/s12879-022-07153-4

IF: 3.7

2022-03-03

BMC Infectious Diseases

Abstract:Abstract Background There is a paucity of knowledge on the long-term outcome in patients diagnosed with COVID-19. We describe a cohort of patients with a constellation of symptoms occurring four weeks after diagnosis causing different degrees of reduced functional capacity. Although different hypothesis have been proposed to explain this condition like persistent immune activation or immunological dysfunction, to date, no physiopathological mechanism has been identified. Consequently, there are no therapeutic options besides symptomatic treatment and rehabilitation. Methods We evaluated patients with symptoms that persisted for at least 4 weeks after COVID-19. Epidemiological and clinical data were collected. Blood tests, including inflammatory markers, were conducted, and imaging studies made if deemed necessary. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain reaction (RT-PCR) in plasma, stool, and urine were performed. Patients were offered antiviral treatment (compassionate use). Results We evaluated 29 patients who reported fatigue, muscle pain, dyspnea, inappropriate tachycardia, and low-grade fever. Median number of days from COVID-19 to positive RT-PCR in extra-respiratory samples was 55 (39–67). Previous COVID-19 was mild in 55% of the cases. Thirteen patients (45%) had positive plasma RT-PCR results and 51% were positive in at least one RT-PCR sample (plasma, urine, or stool). Functional status was severely reduced in 48% of the subjects. Eighteen patients (62%) received antiviral treatment. Improvement was seen in most patients (p = 0.000) and patients in the treatment group achieved better outcomes with significant differences (p = 0.01). Conclusions In a cohort of COVID-19 patients with persistent symptoms, 45% of them have detectable plasma SARS-CoV-2 RNA. Our results indicate possible systemic viral persistence in these patients, who may benefit of antiviral treatment strategies.

infectious diseases
Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Sang Hyun Ra,Euijin Chang,Ji-Soo Kwon,Ji Yeun Kim,JuYeon Son,Woori Kim,Choi Young Jang,Hyeon Mu Jang,Seongman Bae,Jiwon Jung,Min Jae Kim,Yong Pil Chong,Sang-Oh Lee,Sang-Ho Choi,Yang Soo Kim,Keun Hwa Lee,Sung-Han Kim

DOI: https://doi.org/10.3346/jkms.2024.39.e237

2024-09-09

Abstract:Background: The pathophysiological mechanisms underlying the post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) are not well understood. Our study aimed to investigate various aspects of theses mechanisms, including viral persistence, immunological responses, and laboratory parameters in patients with and without PASC. Methods: We prospectively enrolled adults aged ≥ 18 years diagnosed with coronavirus disease 2019 (COVID-19) between August 2022 and July 2023. Blood samples were collected at three time-points: within one month of diagnosis (acute phase) and at 1 month, and 3 months post-diagnosis. Following a recent well-designed definition of PASC, PASC patients were defined as those with a questionnaire-based PASC score ≥ 12 persisting for at least 4 weeks after the initial COVID-19 diagnosis. Results: Of 57 eligible COVID-19 patients, 29 (51%) had PASC, and 28 (49%) did not. The PASC group had significantly higher nucleocapsid protein (NP) antigenemia 3 months after COVID-19 diagnosis (P = 0.022). Furthermore, several cytokines, including IL-2, IL-17A, VEGF, RANTES, sCD40L, IP-10, I-TAC, and granzyme A, were markedly elevated in the PASC group 1 and/or 3 month(s) after COVID-19 diagnosis. In contrast, the median values of several serological markers, including thyroid markers, autoimmune indicators, and stress-related hormones, were within the normal range. Conclusion: Levels of NP antigen and of various cytokines involved in immune responses become significantly elevated over time after COVID-19 diagnosis in PASC patients compared to non-PASC patients. This suggests that PASC is associated with prolonged immune dysregulation resulting from heightened antigenic stimulation.
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection

Michael J. Peluso,Hannah M. Sans,Carrie A. Forman,Alyssa N. Nylander,Hsi-en Ho,Scott Lu,Sarah A. Goldberg,Rebecca Hoh,Viva Tai,Sadie E. Munter,Ahmed Chenna,Brandon C. Yee,John W. Winslow,Christos J. Petropoulos,Jeffrey N. Martin,J.D. Kelly,Matthew S. Durstenfeld,Priscilla Y. Hsue,Peter W. Hunt,Meredith Greene,Felicia C. Chow,Joanna Hellmuth,Timothy J. Henrich,David V. Glidden,Steven G. Deeks

DOI: https://doi.org/10.1212/NXI.0000000000200003

2022-06-15

Neurology: Neuroimmunology and NeuroInflammation

Abstract:Background and Objectives The biologic mechanisms underlying neurologic postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are incompletely understood. Methods We measured markers of neurologic injury (glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL]) and soluble markers of inflammation among a cohort of people with prior confirmed SARS-CoV-2 infection at early and late recovery after the initial illness (defined as less than and greater than 90 days, respectively). The primary clinical outcome was the presence of self-reported CNS PASC symptoms during the late recovery time point. We compared fold changes in marker values between those with and without CNS PASC symptoms using linear mixed-effects models and examined relationships between neurologic and immunologic markers using rank linear correlations. Results Of 121 individuals, 52 reported CNS PASC symptoms. During early recovery, those who went on to report CNS PASC symptoms had elevations in GFAP (1.3-fold higher mean ratio, 95% CI 1.04–1.63, p = 0.02), but not NfL (1.06-fold higher mean ratio, 95% CI 0.89–1.26, p = 0.54). During late recovery, neither GFAP nor NfL levels were elevated among those with CNS PASC symptoms. Although absolute levels of NfL did not differ, those who reported CNS PASC symptoms demonstrated a stronger downward trend over time in comparison with those who did not report CNS PASC symptoms ( p = 0.041). Those who went on to report CNS PASC also exhibited elevations in interleukin 6 (48% higher during early recovery and 38% higher during late recovery), monocyte chemoattractant protein 1 (19% higher during early recovery), and tumor necrosis factor α (19% higher during early recovery and 13% higher during late recovery). GFAP and NfL correlated with levels of several immune activation markers during early recovery; these correlations were attenuated during late recovery. Discussion Self-reported neurologic symptoms present approximately 4 months after SARS-CoV-2 infection are associated with elevations in markers of neurologic injury and inflammation at earlier time points. Some inflammatory pathways seem to be involved months after acute infection. Additional work will be needed to better characterize these processes and to identify interventions to prevent or treat this condition.
Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms: a systematic review of the literature

César Fernández-de-las-Peñas,Juan Torres-Macho,Raymart Macasaet,Jacqueline Veronica Velasco,Abbygail Therese Ver,Timothy Hudson David Culasino Carandang,Jonathan Jaime Guerrero,Ana Franco-Moreno,William Chung,Kin Israel Notarte

DOI: https://doi.org/10.1515/cclm-2024-0036

2024-02-18

Clinical Chemistry and Laboratory Medicine (CCLM)

Abstract:Viral persistence is one of the main hypotheses explaining the presence of post-COVID symptoms. This systematic review investigated the presence of SARS-CoV-2 RNA in plasma, stool, urine, and nasal/oral swab samples in individuals with post-COVID symptomatology. MEDLINE, CINAHL, PubMed, EMBASE, Web of Science databases, as well as medRxiv/bioRxiv preprint servers were searched up to November 25th, 2023. Articles investigating the persistence of SARS-CoV-2 RNA in plasma, stool, urine or nasal/oral swab samples in patients with post-COVID symptoms were included. Methodological quality was assessed using the Newcastle–Ottawa Scale or Cochrane's Risk of Bias (Rob) tool. From 322 studies identified, six studies met all inclusion criteria. The sample included 678 COVID-19 survivors (52 % female, aged from 29 to 66 years). The methodological quality was moderate in 88 % of the studies (n=5/6). Three papers investigated the presence of SARS-CoV-2 RNA in plasma, three studies in nasal/oral swabs, two studies in stool samples, one in urine and one in saliva. The follow-up was shorter than two months (<60 days after) in 66 % of the studies (n=4/6). The prevalence of SARS-CoV-2 RNA ranged from 5 to 59 % in patients with post-COVID symptoms the first two months after infection, depending on the sample tested, however, SARS-CoV-2 RNA was also identified in COVID-19 survivors without post-COVID symptoms (one study). Available evidence can suggest the presence of persistent SARS-CoV-2 RNA in post-COVID patients in the short term, although the biases within the studies do not permit us to make firm assumptions. The association between post-COVID symptoms and SARS-CoV-2 RNA in the samples tested is also conflicting. The lack of comparative group without post-COVID symptoms limits the generalizability of viral persistence in post-COVID-19 condition.

medical laboratory technology
Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort

Mehal Churiwal,Kathleen Tompkins,Gabrielle Streeter,Christy Litel,Sydney Mason,Kelly Lin,Meredith Muller,Srijana Chhetri,Tia Belvin,Christopher Basham,Maureen Whittelsey,Tyler Rapp,Lakshmanane Premkumar,Carla Cerami,Jessica T Lin

DOI: https://doi.org/10.1101/2024.10.27.24316219

2024-10-29

Abstract:Background Early in the SARS-CoV-2 pandemic, description of COVID-19 illness among non-hospitalized patients was limited. Data from household cohorts can help reveal the full spectrum of disease and the potential for long-term sequelae, even in non-severe disease. Methods Daily symptom diaries were collected in a US household cohort of SARS-CoV-2 infection from April to November 2020, during the pre-COVID vaccine period. SARS-CoV-2 nasal viral loads were measured at study entry and weekly until day 21; serologic testing was performed at study entry and day 28. A subset of volunteers underwent an additional assessment 8-10 months later. Participants who met the criteria for early infection—testing antibody-negative at study entry but PCR-positive either at baseline or during follow-up—were included in this analysis (n=143). Results Daily symptoms were ascertained in 143 outpatients with acute COVID-19, including 60 index cases who sought testing and 83 of their household contacts. Asymptomatic cases comprised 16% (13/83) of SARS-CoV-2 infections detected among household contacts. Among 119 persons with mild or moderate illness, the number of symptoms peaked 3 or 4 days after symptom onset. Fever and anosmia occurred in nearly half of participants. Symptom severity was associated with increased age, viral load, and cardiovascular disease. Increased BMI was associated with a higher antibody level at day 28, independent of symptom severity. Those with a higher day 28 antibody level were more likely to develop symptoms consistent with post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID-19, 8-10 months later. Conclusions Fever, anosmia, as well as asymptomatic infection were common features of COVID-19 non-severe illness when the D614G variant circulated in the US, before the availability of vaccines or outpatient therapies. Antibody levels following acute infection were linked to the development of symptoms of PASC 8-10 months later.
Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection

Chansavath Phetsouphanh,David Darley,Daniel B Wilson,Annett Howe,C. Mee Ling Munier,Sheila K Patel,Jennifer A Juno,Louise M Burrell,Stephen J Kent,Gregory J Dore,Anthony D Kelleher,Gail V Matthews

DOI: https://doi.org/10.1101/2021.06.01.21257759

2021-06-03

Abstract:Abstract A proportion of patients surviving acute COVID-19 infection develop post-COVID syndrome (long COVID) encompassing physical and neuropsychiatric symptoms lasting longer than 12 weeks. Here we studied a prospective cohort of individuals with long COVID compared to age/gender matched subjects without long COVID (from the ADAPT study), healthy donors and individuals infected with other non-SARS CoV2 human coronaviruses (the ADAPT-C study). We found highly activated innate immune cells and an absence of subsets of un-activated naïve T and B cells in peripheral blood of long COVID subjects, that did not reconstitute over time. These activated myeloid cells may contribute to the elevated levels of type I (IFN-β) and III interferon (IFN-λ1) that remained persistently high in long COVID subjects at 8 months post-infection. We found positive inter-analyte correlations that consisted of 18 inflammatory cytokines in symptomatic long COVID subjects that was not observed in asymptomatic COVID-19 survivors. A linear classification model was used to exhaustively search through all 20475 combinations of the 29 analytes measured, that had the strongest association with long COVID and found that the best 4 analytes were: IL-6, IFN-γ, MCP-1 (CCL2) and VCAM-1. These four inflammatory biomarkers gave an accuracy of 75.9%, and an F1 score of 0.759, and have also previously been associated with acute severe disease. In contrast, plasma ACE2 levels, while elevated in the serum of people previously infected with SARS-CoV-2 were not further elevated in subjects with long COVID symptoms. This work defines immunological parameters associated with long COVID and suggests future opportunities to prevention and treatment.

Ovarian low-grade serous carcinoma: a comprehensive update.

Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study

Early biological markers of post-acute sequelae of SARS-CoV-2 infection

Persistence of S1 Spike Protein in CD16+ Monocytes up to 245 Days in SARS-CoV-2 Negative Post COVID-19 Vaccination Individuals with Post-Acute Sequalae of COVID-19 (PASC)-Like Symptoms

Viral persistence, reactivation, and mechanisms of long COVID

Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19

Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infection

Prevalence of persistent SARS-CoV-2 in a large community surveillance study

A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings

Patient and immunological factors associated with delayed clearance of mucosal SARS-CoV-2 RNA and symptom persistence

Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals

Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

The Potential Role of Viral Persistence in the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

Viral, Immunologic, and Laboratory Parameters in Patients With and Without Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection

Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms: a systematic review of the literature

Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort

Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection